-
Marchés
-
Actions
Sustainable finance2025 Euronext ESG Trends ReportLire la suiteA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLire la suiteInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fonds
-
Obligations
European Defence BondsGroupe BPCE lists the first bondLire la suiteFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Produits Structurés
-
Dérivés
Where European Government Bonds Meet the FutureFixed Income derivativesLire la suiteTrade mini bond futures on main European government bonds
-
Marchandises
- Vue d'ensemble
- Vue d'ensemble
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Règlement livraison
- Spécifications et dispositions
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLire la suiteEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLire la suiteJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
NEOVACS
Identification
Listing sponsor / Agent
Invest Securities
Symbole
ALNEV
Code ISIN
FR0004032746
Exchange / Market
Euronext Growth
Trading location
Paris
ICB
Biotechnology
Description de l'activité
Fondée en 1993 par Daniel Zagury (l'un des plus éminents spécialistes de l'immunologie), à la suite d’un spin-off de l’Université Pierre et Marie Curie (Paris), Néovacs est leader dans le domaine de l’immunothérapie active afin de traiter les troubles liés à la surexpression de cytokines en se focalisant notamment sur les maladies auto-immunes inflammatoires ainsi que le cancer.
Site internet
http://www.neovacs.fr
Issuer website
http://www.neovacs.fr
Operation
Date de l'IPO
jeu 15/04/2010
Type d'IPO
Initial Public offering
Catégorie
IPO